Pfizer Expects 2024 Adjusted EPS Of $2.45-$2.65 Compared To Prior Guidance Of $2.15-$2.35 And Consensus Of $2.37
Portfolio Pulse from Benzinga Newsdesk
Pfizer has updated its financial guidance for 2024, raising its adjusted EPS forecast to $2.45-$2.65 from the previous $2.15-$2.35, and increasing its revenue projection to $59.5-$62.5 billion from $58.5-$61.5 billion. The company also lowered its effective tax rate on adjusted income to approximately 13% from 15%.
July 30, 2024 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer has raised its 2024 adjusted EPS forecast to $2.45-$2.65 from the previous $2.15-$2.35, and increased its revenue projection to $59.5-$62.5 billion from $58.5-$61.5 billion. The effective tax rate on adjusted income has been lowered to approximately 13% from 15%.
The upward revision in EPS and revenue guidance, along with a lower effective tax rate, is likely to positively impact Pfizer's stock price in the short term as it indicates stronger financial performance and profitability.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100